Entrectinib-d 8

Overview

Entrectinib -d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib ( HY-12678 ). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC 50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.

Application

Products | Products > Signaling Pathways > Others | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ROS Kinase | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-12678S1
• CAS No.: 2251773-94-9
• Molecular Formula: C31H26D8F2N6O2
• Molecular Weight: 568.69
• Purity: 99.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source